GlassScriptPhysician profile
Daniel H Davis
NPI 1154468270
$1,771.56
in general payments reported to CMS, 2019-2025
32 companies · $227 in 2025
The $227 reported for 2025 was more than what a typical Obstetrics provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $350 · 2020: $69.10 · 2021: $146 · 2022: $273 · 2023: $465 · 2024: $241 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $933.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $933.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $251.98 | 2019-2023 | Orilissa |
| Pfizer INC. | $248.26 | 2019-2023 | |
| Hologic Sales and Service, LLC | $112.77 | 2019-2024 | Novasure |
| Bayer Healthcare Pharmaceuticals INC. | $104.51 | 2019-2025 | |
| Axonics, INC. | $90.62 | 2023 | Axonics |
| Biogen, INC. | $89.82 | 2025 | Zurzuvae |
| Astellas Pharma US INC | $88.84 | 2021-2024 | Veozah |
| Sumitomo Pharma America, INC. | $82.72 | 2024 | Myfembree |
| Organon LLC | $76.40 | 2021-2025 | Jada System, Nexplanon |
| Myovant Sciences INC. | $61.93 | 2022 | |
| Exeltis, USA INC. | $53.19 | 2021-2025 | Slynd |
| Therapeuticsmd, INC. | $52.98 | 2019-2022 | |
| Coloplast Corp | $44.55 | 2019-2023 | Saffron |
| Pacira Pharmaceuticals Incorporated | $37.58 | 2019-2024 | Exparel |
| Boston Scientific Corporation | $37.54 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $36.71 | 2022-2023 | |
| Lupin INC. | $29.12 | 2019-2020 | |
| Coopersurgical, INC. | $27.69 | 2019-2022 | |
| Duchesnay USA Incorporated | $25.82 | 2019 | |
| Agile Therapeutics, INC. | $24.02 | 2021 | |
| Dexcom, INC. | $20.78 | 2025 | Dexcom G6 Transmitter |
| Millicent US INC | $18.33 | 2025 | Femlyv |
| Amag Pharmaceuticals, INC. | $17.79 | 2019 | |
| Intuitive Surgical, INC. | $17.39 | 2025 | |
| Novartis Pharmaceuticals Corporation | $17.23 | 2019 | |
| Smith+Nephew, INC. | $16.91 | 2019 | |
| Shield Therapeutics INC | $16.72 | 2024 | |
| Daiichi Sankyo INC. | $14.91 | 2019 | |
| Avanos Medical | $14.60 | 2019 | |
| Roche Diagnostics Corporation | $14.42 | 2019 | |
| Novo Nordisk INC | $14.00 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $11.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.